Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.

STUDY OBJECTIVES To compare clinical, electrophysiologic, and biologic data in narcolepsy without cataplexy with low (≤ 110 pg/ml), intermediate (110-200 pg/ml), and normal (> 200 pg/ml) concentrations of cerebrospinal fluid (CSF) hypocretin-1. SETTING University-based sleep clinics and laboratories. PATIENTS Narcolepsy without cataplexy (n = 171) and control patients (n = 170), all with available CSF hypocretin-1. DESIGN AND INTERVENTIONS Retrospective comparison and receiver operating characteristics curve analysis. Patients were also recontacted to evaluate if they developed cataplexy by survival curve analysis. MEASUREMENTS AND RESULTS The optimal cutoff of CSF hypocretin-1 for narcolepsy without cataplexy diagnosis was 200 pg/ml rather than 110 pg/ml (sensitivity 33%, specificity 99%). Forty-one patients (24%), all HLA DQB1*06:02 positive, had low concentrations (≤ 110 pg/ml) of CSF hypocretin-1. Patients with low concentrations of hypocretin-1 only differed subjectively from other groups by a higher Epworth Sleepiness Scale score and more frequent sleep paralysis. Compared with patients with normal hypocretin-1 concentration (n = 117, 68%), those with low hypocretin-1 concentration had higher HLA DQB1*06:02 frequencies, were more frequently non-Caucasians (notably African Americans), with lower age of onset, and longer duration of illness. They also had more frequently short rapid-eye movement (REM) sleep latency (≤ 15 min) during polysomnography (64% versus 23%), and shorter sleep latencies (2.7 ± 0.3 versus 4.4 ± 0.2 min) and more sleep-onset REM periods (3.6 ± 0.1 versus 2.9 ± 0.1 min) during the Multiple Sleep Latency Test (MSLT). Patients with intermediate concentrations of CSF hypocretin-1 (n = 13, 8%) had intermediate HLA DQB1*06:02 and polysomnography results, suggesting heterogeneity. Of the 127 patients we were able to recontact, survival analysis showed that almost half (48%) with low concentration of CSF hypocretin-1 had developed typical cataplexy at 26 yr after onset, whereas only 2% had done so when CSF hypocretin-1 concentration was normal. Almost all patients (87%) still complained of daytime sleepiness independent of hypocretin status. CONCLUSION Objective (HLA typing, MSLT, and sleep studies) more than subjective (sleepiness and sleep paralysis) features predicted low concentration of CSF hypocretin-1 in patients with narcolepsy without cataplexy.

[1]  S. Nevsimalova,et al.  Clinical features of childhood narcolepsy. Can cataplexy be foretold? , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[2]  Y. Inoue,et al.  Relationship between clinical characteristics of narcolepsy and CSF orexin‐A levels , 2011, Journal of sleep research.

[3]  M. Cao.  Advances in narcolepsy. , 2010, The Medical clinics of North America.

[4]  S. Gammeltoft,et al.  P9-11 Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population , 2010, Clinical Neurophysiology.

[5]  T. Shimohata,et al.  Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. , 2009, Archives of neurology.

[6]  C. Baumann,et al.  Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome. , 2009, Sleep medicine.

[7]  S. Nevsimalova,et al.  Does age at the onset of narcolepsy influence the course and severity of the disease? , 2009, Sleep medicine.

[8]  J. Siegel,et al.  Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. , 2009, Sleep.

[9]  C. Gieger,et al.  Erratum: Narcolepsy is strongly associated with the T-cell receptor alpha locus , 2009, Nature Genetics.

[10]  S. Nevsimalova,et al.  Narcolepsy in childhood. , 2009, Sleep medicine reviews.

[11]  E. Mignot,et al.  CSF hypocretin-1 assessment in sleep and neurological disorders , 2008, The Lancet Neurology.

[12]  Seockhoon Chung,et al.  Prevalence of narcolepsy‐cataplexy in Korean adolescents , 2008, Acta neurologica Scandinavica.

[13]  K. Gautvik,et al.  CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. , 2007, Sleep.

[14]  R. Casamitjana,et al.  Análisis comparativo de un grupo de pacientes con narcolepsia-cataplejía, narcolepsia sin cataplejía e hipersomnia idiopática , 2007 .

[15]  E. Mignot,et al.  A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. , 2006, Sleep.

[16]  H. Shibasaki,et al.  Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings. , 2006, Sleep.

[17]  T. Pollmächer,et al.  EFNS guidelines on management of narcolepsy , 2006, European journal of neurology.

[18]  C. Drake,et al.  The prevalence of multiple sleep-onset REM periods in a population-based sample. , 2006, Sleep.

[19]  T. Young,et al.  Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. , 2006, Brain : a journal of neurology.

[20]  C. Baumann,et al.  Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  J. Touchon,et al.  CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions , 2003, Journal of neurology, neurosurgery, and psychiatry.

[22]  M. Thorpy.  Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy , 2003, Current neurology and neuroscience reports.

[23]  V. Pankratz,et al.  Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. , 2002, Sleep.

[24]  E. Mignot,et al.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. , 2002, Archives of neurology.

[25]  R G Priest,et al.  Prevalence of narcolepsy symptomatology and diagnosis in the European general population , 2002, Neurology.

[26]  V. Pankratz,et al.  The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. , 2002, Sleep.

[27]  E. Mignot,et al.  Clinical aspects of narcolepsy-cataplexy across ethnic groups. , 2002, Sleep.

[28]  J. Montplaisir,et al.  Age at onset of narcolepsy in two large populations of patients in France and Quebec , 2001, Neurology.

[29]  R. Biancheri,et al.  Hypersomnia in the Prader Willi syndrome: clinical-electrophysiological features and underlying factors , 2001, Clinical Neurophysiology.

[30]  E. Mignot,et al.  Narcolepsy:Clinical Features, New Pathophysiologic Insights, and Future Perspectives , 2001, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[31]  Sebastiaan Overeem,et al.  Hypocretin (orexin) deficiency in human narcolepsy , 2000, The Lancet.

[32]  H. Kraemer,et al.  Validation of a cataplexy questionnaire in 983 sleep-disorders patients. , 1999, Sleep.

[33]  C. Guilleminault,et al.  HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. , 1997, Sleep.

[34]  R. Chervin,et al.  Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. , 1997, Sleep.

[35]  D. Kleinbaum.  Survival Analysis: A Self-Learning Text , 1997 .

[36]  S Koskimies,et al.  The prevalence of narcolepsy: An epidemiological study of the Finnish Twin Cohort , 1994, Annals of neurology.

[37]  D. Greenblatt,et al.  The International Classification of Sleep Disorders , 1992 .

[38]  M. Johns,et al.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale. , 1991, Sleep.

[39]  R. Daroff,et al.  The International Classification of Sleep Disorders , 1991, Neurology.

[40]  M. Carskadon,et al.  Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. , 1986, Sleep.

[41]  C. Guilleminault,et al.  REM sleep episodes during the Multple Sleep Latency Test in narcoleptic patients. , 1979, Electroencephalography and clinical neurophysiology.

[42]  M. Carskadon,et al.  Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. , 1978, Electroencephalography and clinical neurophysiology.

[43]  J. Santamaria,et al.  [Comparative analysis of patients with narcolepsy-cataplexy, narcolepsy without cataplexy and idiopathic hypersomnia]. , 2007, Medicina clínica (Ed. impresa).

[44]  Zhang Jing-xing,et al.  Brief introduction to second edition of International Classification of Sleep Disorders:Diagnostic and Coding Manual , 2007 .

[45]  M. Littner,et al.  Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. , 2005, Sleep.

[46]  R. Chervin,et al.  Sleep onset REM periods during multiple sleep latency tests in patients evaluated for sleep apnea. , 2000, American journal of respiratory and critical care medicine.

[47]  Dc Washington.  Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .

[48]  Rupert G. Miller,et al.  Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.